Wexford Capital LP Dia Medica Therapeutics Inc. Transaction History

Wexford Capital LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$1.8 - $5.04 $159,948 - $447,854	-88,860 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$2.07 - $4.88 $644,059 - $1.52 Million	-311,140 Reduced 77.79%	88,860 $184,000
Q2 2019 Aug 14, 2019	SELL	$2.7 - $4.96 $202,500 - $372,000	-75,000 Reduced 15.79%	400,000 $1.98 Million
Q4 2018 Feb 14, 2019	BUY	$2.65 - $9.2 $1.26 Million - $4.37 Million	475,000 New	475,000 $1.38 Million

4.22M

8.2K

200

Ticker DMAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,443,100
Market Cap $128M
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...

Get notified when there are updates to the investment portfolio of Wexford Capital LP, based on Form 13F filings with the SEC.

Stay updated on Wexford Capital LP with notifications on news.